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Abstract
Background: Several studies have shown that NDRG2 mRNA is down-regulated or undetectable in various human
cancers and cancer cell-lines. Although the function of NDRG2 is currently unknown, high NDRG2 expression
correlates with improved prognosis in high-grade gliomas, gastric cancer and hepatocellular carcinomas.
Furthermore, in vitro studies have revealed that over-expression of NDRG2 in cell-lines causes a significant
reduction in their growth. The aim of this study was to examine levels of NDRG2 mRNA in several human cancers,
with focus on breast cancer, by examining affected and normal tissue.
Methods: By labelling a human Cancer Profiling Array with a radioactive probe against NDRG2, we evaluated the
level of NDRG2 mRNA in 154 paired normal and tumor samples encompassing 19 different human cancers.
Furthermore, we used quantitative real-time RT-PCR to quantify the levels of NDRG2 and MYC mRNA in thyroid
gland cancer and breast cancer, using a distinct set of normal and tumor samples.
Results: From the Cancer Profiling Array, we saw that the level of NDRG2 mRNA was reduced by at least 2-fold in
almost a third of the tumor samples, compared to the normal counterpart, and we observed a marked decreased
level in colon, cervix, thyroid gland and testis. However, a Benjamini-Hochberg correction showed that none of the
tissues showed a significant reduction in NDRG2 mRNA expression in tumor tissue compared to normal tissue.
Using quantitative RT-PCR, we observed a significant reduction in the level of NDRG2 mRNA in a distinct set of
tumor samples from both thyroid gland cancer (p = 0.02) and breast cancer (p = 0.004), compared with normal
tissue. MYC mRNA was not significantly altered in breast cancer or in thyroid gland cancer, compared with normal
tissue. In thyroid gland, no correlation was found between MYC and NDRG2 mRNA levels, but in breast tissue we
found a weakly significant correlation with a positive r-value in both normal and tumor tissues, suggesting that
MYC and NDRG2 mRNA are regulated together.
Conclusion: Expression of NDRG2 mRNA is reduced in many different human cancers. Using quantitative RT-PCR,
we have verified a reduction in thyroid cancer and shown, for the first time, that NDRG2 mRNA is statistically
significantly down-regulated in breast cancer. Furthermore, our observations indicate that other tissues such as
cervix and testis can have lower levels of NDRG2 mRNA in tumor tissue compared to normal tissue.
Background
The transformation of normal cells into cancer cells is
generally believed to rely on genetic or epigenetic
changes in the genome. These changes often activate
oncogenes and/or inactivate tumor suppressor genes.
The recently described N-Myc Downstream Regulated
Gene 2 (NDRG2) is down-regulated in a variety of
human tumors, including colorectal, liver and thyroid
cancers as well as glioblastoma [1-5]. Furthermore, ele-
vated expression of NDRG2 in tumors correlates with
an improved prognosis in gastric cancer, high-grade
glioma and hepatocellular carcinomas [2,6,7]. Several in
vitro studies have demonstrated a reduced cell growth
when NDRG2 was over-expressed in cell-lines lacking
endogenous expression [5,8]. These data suggest that
NDRG2 might have a role in suppressing carcinogenesis.
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NDRG2 is one of four members belonging to the NDRG
family. In contrast to NDRG1, however, NDRG2 does
not appear to be down-regulated by N-myc in vivo [9].
All four NDRG family members possess an a/b-
hydrolase fold domain but whether or not they have
enzymatic activity is presently unclear.
Northern blot analysis was previously used to establish
the mRNA expression pattern of NDRG2 in normal tis-
sues and it has been shown to have the highest expres-
sion in brain, heart, skeletal muscle, kidney and liver and
lowest expression in tissues such as colon, spleen, pla-
centa and lung [5,10,11]. How NDRG2 is regulated is not
well understood, but recently it was shown that Myc, via
Miz-1, can repress NDRG2 expression [12] and that the
Wilms’ tumor gene 1 protein as well as p53 can induce
expression of NDRG2 [13,14]. Furthermore, studies have
shown that NDRG2 transcription can be subjected to an
epigenetic repression through promoter methylation,
leading to a decreased expression [15,16]. Finally,
NDRG2 protein contains several phosphorylation sites
[17] suggesting a completely separate regulatory mechan-
ism via a phosphorylation-dephosphorylation cycle.
Based on our current understanding, NDRG2 is a can-
didate tumor suppressor gene. To further understand
how NDRG2 is involved in carcinogenesis, we need to
know more about the regulation, distribution and func-
tion of NDRG2. In this paper, we present a broad profile
of NDRG2 expression in human cancers with focus on
breast cancer. Our data from 19 different cancers indi-
cates that NDRG2 is up-regulated in around 8% of all
tumors examined, unaltered in 62% of all cases and that
approximately a third of the tumor samples show down-
regulation of NDRG2 compared to the corresponding
normal tissue. By quantifying the level of NDRG2
mRNA in 35 breast cancer samples, we observed a sta-
tistically significant down-regulation of NDRG2 in
tumor samples compared to normal tissue. We also
quantified the level of MYC in the same breast cancer
samples to investigate whether or not a high level of
MYC expression could be responsible for the observed
NDRG2 down-regulation. In our hands, we observed a
positive correlation, indicating that MYC and NDRG2
are co-regulated. Thus, another regulatory pathway than
repression by Myc appears to reduce NDRG2 mRNA
levels in breast cancer.
Methods
Cancer Profiling Array II
The Cancer Profiling Array II (CPA II, Clontech) was
hybridised with 50 ng of radioactively labelled NDRG2
probe according to the manufacturer’s instructions. The
460 bp NDRG2 probe was generated by PCR using the
primers 5’CTCACTCTGTGGAGACACCAT3’ and
5’GGGTGATATCACCTCCACGCT3’. The hybridised
array was exposed to a phosphorimaging screen for 24
hours and the intensity of each spot was quantified
using ImageQuant (Molecular Dynamics). The CPA II
consists of paired cDNA samples generated from the
total RNA of normal and tumor tissue. Because the
array is normalised for several housekeeping genes,
quantification of the hybridisation signal provides an
estimate of relative transcript abundance. Furthermore,
the CPA II was hybridised with a human ubiquitin con-
trol cDNA probe provided by the manufacturer and
exposed for 48 hours. All samples showed uniform
expression of ubiquitin confirming the normalisation by
the manufacturer (data not shown).
TissueScan mRNA quantification
Breast and thyroid cancer TissueScan qPCR Arrays
(Origene Technologies, Rockville MD) were used to
quantify and normalise the level of NDRG2 and MYC to
the expression level of b-actin. The TissueScan Arrays
consist of pre-normalized cDNA from both normal and
tumor tissues. The commercial supplier has confirmed
that the removal of human tissue was performed with
the approval of an Institutional Review Board ethics
committee within each medical center. The medical
centers from which the tissue was banked represented
major academic medical centers within the US. Tissue
and data collection conform to Federal requirements
and informed consent was obtained from all human
subjects. According to the manufacturer, samples were
selected based on tumor content (minimally 50% tumor)
as determined by microscopic pathology analysis. Based
on a pathology report the tumors were partly classified,
following the tumor-node-metastasis (TNM) staging sys-
tem, according to their size/extent (TI-TIVC). The nor-
mal samples were taken from patients diagnosed with
cancer, but the tissues were harvested from normal
regions. The quantification was performed on an ABI
7300 sequence detector as previously described [1] or as
recommended by the manufacturer. The primers and
probes for NDRG2 have previously been described [1].
Primers and probes for b-actin (part no. 4310881) and
MYC (assay ID Hs00153408 m1) were obtained from
Applied Biosystems.
In a validation experiment using a control sample, a 2-
fold dilution series was produced and assayed for
NDRG2, MYC and b-actin expression as described in
the comparative Ct method [18]. When Ct values were
plotted against log dilution it was shown that the assays
were quantitative over a range of 128-fold dilution for
the NDRG2/b-actin assay and over a 512-fold dilution
for the MYC/b-actin assay, using a threshold of 0.2 for
b-actin, 0.07 for NDRG2 and 0.15 for MYC.
NDRG2, MYC and b-actin mRNAs were quantified in
separate wells in triplicate. The standard deviation of
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the same sample (internal and positive control) in sepa-
rate experiments was 20%, 10% and 20% for NDRG2,
MYC and b-actin respectively in thyroid tissue, and
27%, 10% and 16% for NDRG2, MYC and b-actin
respectively in breast tissue, indicating a day-to-day var-
iation of the assay. Negative controls (without conver-
sion of RNA into cDNA) and positive controls were
included in all sets.
For both thyroid and breast cancer samples, some data
were excluded either due to Ct values being too low and
outside the standard curve or because the mRNA levels
were below the detection level. In general, the levels of
both NDRG2 and MYC were lower in thyroid tissue than
breast tissue samples compared to b-actin, which was
equally expressed in both tissues. The distribution of
gender and age among cases whose tissue was included
in the final analysis is presented in Tables 1 and 2.
Statistical analysis
GraphPad Prism 4 was used for all the statistic calcula-
tions and p values < 0.05 were considered significant for
all tests. The paired two-tailed t-test was used for
comparisons of the CPA data and p-values were subse-
quently corrected for type I errors using the Benjamini-
Hochberg method. For the quantitative RT-PCR data for
the breast and thyroid tissues, the Mann-Whitney test
was used to compare mean values between normal and
tumor samples, since the variances in those samples
were different. The non-parametric Kruskal-Wallis test
was used on the different tumor stages TI through
TIIIC groups, since the variances in the groups were dif-
ferent. For correlation analyses we used Spearman’s cor-
relation test due to the number of samples and since
the data did not follow a Gaussian distribution.
Results
Expression profile of NDRG2 in human cancers
By hybridising a CPA with a radioactive labelled probe it
was possible to examine the levels of NDRG2 mRNA in
19 different human cancers, distributed as 154 paired tis-
sue samples, and 9 different cell lines. Samples on the
CPA have been normalised by the manufacturer on the
basis of three different housekeeping genes. As shown in
Figure 1, NDRG2 was detected at varying expression
levels in all normal tissues. Dot intensities from the CPA
and corresponding patient data are available as supple-
mentary data (Additional file 1), except for colon cancer
which was published previously [1]. With regards to nor-
mal tissue samples, the highest expression of NDRG2 was
seen in liver, prostate, breast, uterus, thyroid gland, testis
and skin. An intermediate expression level was seen in
vulva, trachea, kidney, colon, ovary, cervix, small intestine
and pancreas and, finally, lowest expression was observed
in bladder, lung, stomach and rectum.
We defined down- and up-regulation as changes in the
mRNA level between tumor and corresponding normal tis-
sue to less than or equal to 0.5-fold or more than or equal
to 2-fold, respectively. Analysing data from the CPA based
on these criteria revealed that 95 out of 154 samples (62%)
showed unaltered NDRG2 mRNA levels in tumors. How-
ever, 46 of the 154 samples analysed (30%) showed down-
regulation and in 13 of 154 samples (8%), an up-regulation
of the NDRG2 mRNA level was observed (Table 3).
The 19 different cancer forms did not all show unidir-
ectional changes in NDRG2 mRNA levels (Table 3).
Liver cancer showed, as the only tissue, down-regulation
in all samples. Tissue samples from cervix, colon, ovary,
skin, testis, thyroid gland and vulva all showed both
down-regulation and unaltered mRNA levels. Prostate,
small intestine and trachea samples were all unaltered,
while bladder and stomach had unaltered or up-
regulated levels of NDRG2 mRNA. Finally, breast, kidney,
lung, pancreas, rectum and uterus showed a mixture of
down-regulated, unaltered and up-regulated levels.
Calculating a paired two-tailed t-test on our dataset of
154 paired samples, we obtained statistically significant
p-values for colon (p = 0.008; n = 10), cervix (p = 0.02;
n = 10), thyroid gland (p = 0.005; n = 10) and testis
(p = 0.03; n = 10) only. However, after correcting for
type I errors, using the Benjamini-Hochberg correction,
we found that none of these tissues exhibited significant
differences between normal and tumor tissue.
Levels of NDRG2 and MYC mRNA in thyroid gland cancer
To elaborate on some of the data obtained from the
CPA, we decided to quantify NDRG2 mRNA in sample
Table 1 Characteristics of cases with thyroid gland cancer
Normal1 TI TII TIII TIVA TIVC
n 4 9 3 6 2 1
Females 4 7 2 3 1 -
Males - 2 1 3 1 1
Mean age 47.3 40.3 59.3 65.5 48.5 80.0
SD 16.3 15.0 3.2 9.4 5.0 -
1Normal samples were control tissue taken from patients diagnosed with
cancer. SD = standard deviation
Table 2 Characteristics of cases with breast cancer
Normal1 TI TIIA TIIB TIIIA TIIIC
n 7 10 13 7 8 3
Females 7 10 13 7 8 3
Males - - - - - -
Mean age 43.1 63.3 58.2 53.6 55.3 57.7
SD 9.6 10.6 13.9 6.0 13.9 9.6
1Normal samples were control tissue taken from patients diagnosed with
cancer. SD = standard deviation
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sets obtained from patients diagnosed with thyroid gland
cancer and breast cancer. Both sets included normal and
tumor tissues and, furthermore, the tumor samples cov-
ered stages TI-TIV. The level of NDRG2 mRNA in nor-
mal and tumor samples from thyroid gland is shown in
Figure 2 and mean values with 95% confidence intervals
are presented in Table 4. Using a two-tailed Mann-
Whitney test revealed a significant reduction in NDRG2
mRNA levels in tumor tissue compared to the corre-
sponding normal tissue (p = 0.02), albeit based on a
small sample set.
Zhang et al. have previously shown that the expression
of NDRG2 can be repressed by the Myc oncoprotein via
Miz-1 [12]. In order to look further into a possible rela-
tionship between NDRG2 and MYC expression, we also
quantified the levels of MYC mRNA in the same tissue
samples that were analysed for NDRG2 mRNA levels
(Figure 2; Table 4). Examining the level of MYC mRNA
did not reveal a significant change between normal and
cancerous thyroid gland tissues. In order to analyse for a
covariation between NDRG2 and MYC, we calculated the
correlation coefficient using a Spearman’s correlation
test. It was not possible to calculate a correlation coeffi-
cient for the normal thyroid gland samples due to too
few samples, but for thyroid gland tumors we did not
observe a correlation.
Levels of NDRG2 and MYC mRNA in breast cancer
Quantification of NDRG2 mRNA in breast cancer tissue
showed a clear reduction in the level of NDRG2 mRNA
Figure 1 NDRG2 mRNA levels in 19 different human tissues composed of paired normal and tumor samples. The Cancer Profiling Array
II was hybridised with a 32P-labelled probe for NDRG2. Each dot represents one tissue sample and the intensity of each dot was measured with
ImageQuant. In 30% of tumor samples, NDRG2 mRNA levels were down-regulated by at least 2-fold compared to the corresponding normal
tissue. In 8% of tumor samples, NDRG2 mRNA levels were increased by 2-fold or more compared to the corresponding normal tissue.
N = normal tissue and T = tumor tissue.
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in tumors compared to normal tissue (Figure 3,
Table 4). The reduction in NDRG2 mRNA was statisti-
cally significant by a two-tailed Mann-Whitney test
(p = 0.004). Classifying tumor samples according to
tumor stages TI to TIIIC showed that the different
tumor stages did not have significantly different mean
values using the Kruskal-Wallis test (p = 0.738, data not
shown).
In the same set of breast cancer samples, we quanti-
fied the level of MYC mRNA (Figure 3; Table 4).
Although MYC mRNA levels appeared lower in all
tumors compared to normal tissue, this was not statisti-
cally significant, using a two-tailed Mann-Whitney test
(p = 0.0725). Just as for NDRG2, we did not observe any
significant differences between mean values when ana-
lysing tumors from stages TI - TIIIC (Kruskal-Wallis
test, p = 0.180 and data not shown).
We used a Spearman’s correlation test in order to
analyse for a possible relationship between NDRG2 and
MYC expression. For breast cancer we obtained a statis-
tically significant, but weak, correlation coefficient of r =
0.8571 (p = 0.0238) for normal samples and r = 0.4234
(p = 0.0113) for tumor samples. A positive correlation
coefficient between 0-1 indicates that the two variables
being analysed either decrease or increase together.
Discussion
In order to understand the initiation and progression of
cancer, it is important to identify the genes and
mechanisms involved. In this paper, we have examined
the expression of NDRG2, a recently discovered gene
with a proposed tumor suppressor activity, using a com-
mercially available cancer profiling array covering 19 dif-
ferent human cancer forms. One third of all tumor
samples analysed showed down-regulation of NDRG2
mRNA levels by 2-fold or more compared to corre-
sponding normal tissue, suggesting that either the
regulators of NDRG2 are generally affected or that
NDRG2 is often inactivated in tumors. Several tumor
types (cervix, colon, testis and thyroid) from the CPA
showed a statistically significant reduction of NDRG2
mRNA when analysed separately (t-test), but when
Table 3 Expression analysis of NDRG2 using a cancer profiling array
Tissue Number of
samples
Paired two-
tailed t-test
Down-regulated (Tumor/
normal ratio ≤ 0.5)
Unaltered (Tumor/normal
ratio between 0.51-1.99)
Up-regulated (Tumor/
normal ratio ≥ 2.0)
Benjamini-
Hochberg
correction
Down-regulated NDRG2 mRNA levels
Liver 3 NS 3 - - NS
Down-regulated or unaltered NDRG2 mRNA levels
Cervix 10 0.023 3 7 - NS
Colon 10 0.008 4 6 - NS
Ovary 10 NS 3 7 - NS
Skin 10 NS 4 6 - NS
Testis 10 0.030 7 3 - NS
Thyroid
Gland
10 0.005 5 5 - NS
Vulva 5 NS 2 3 - NS
Unaltered NDRG2 mRNA levels
Prostate 4 NS - 4 - NS
Small
Intestine
7 NS - 7 - NS
Trachea 3 NS - 3 - NS
Unaltered or up-regulated NDRG2 mRNA levels
Bladder 5 NS - 3 2 NS
Stomach 10 NS - 8 2 NS
Down-regulated, unaltered or up-regulated NDRG2 mRNA levels
Breast 10 NS 4 5 1 NS
Kidney 10 NS 3 4 3 NS
Lung 10 NS 1 8 1 NS
Pancreas 7 NS 1 5 1 NS
Rectum 10 NS 3 6 1 NS
Uterus 10 NS 3 5 2 NS
NS = not significant
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corrected together for type I errors (Benjamini-Hoch-
berg correction) covering the whole array, none of them
retained significance. However, analysing both colon and
thyroid cancer in a more quantitative manner and using
larger sample sets, we and others have demonstrated a
clear and significant decrease in NDRG2 mRNA levels
in both cancer types [1,3]. Similarly, we observed lower
levels in all 3 liver cancer samples, which was recently
confirmed in a larger study [2]. From the CPA results,
we would also like to highlight tissues such as cervix
and testis as candidate tissues with a potential decrease
of NDRG2 mRNA between normal and tumor tissues.
The sample size for each cancer type on the CPA was
between 3 to 10 paired normal and tumor samples.
A conclusion from the CPA is therefore not straightfor-
ward and we only used the array data as a survey-type
study to identify candidate tissues for subsequent quan-
tification studies.
In the case of both breast and thyroid cancer, we ana-
lysed 5-7 normal and around 40 tumor samples by
quantitative RT-PCR. All samples showed a uniform
level of b-actin mRNA, indicating equivalent amounts of
mRNA in each sample. However, in some cases the
NDRG2 levels were too low (outside the standard curve)
or even undetectable. In the case of thyroid cancer, 2
normal and the majority of tumor samples (34) were
discarded due to too low or undetectable mRNA levels.
Figure 2 NDRG2 mRNA levels are down-regulated in tumor
tissue from thyroid cancer patients. mRNA expression of NDRG2
and Myc, respectively, was determined by real-time RT-PCR and
normalised to b-actin in normal and affected tissue from thyroid
cancer patients. Lines represent mean expression. * p < 0.05
compared to the normal group using a two-tailed Mann-Whitney
test. No correlation was found between NDRG2 and Myc mRNA
levels using a Spearman’s correlation test.
Table 4 Expression values in thyroid gland and breast tissues
Mean value in normal tissue (95% CI) Mean value in tumor tissue (95% CI)
Thyroid gland
NDRG2 0.0073 (0.0028-0.0112) 0.0030 (0.0016-0.0044)
MYC 0.0070 (-0.0028-0.0168) 0.0034 (0.0021-0.0046)
Breast
NDRG2 0.0256 (0.0063-0.0448) 0.0045 (0.0027-0.0064)
MYC 0.0589 (0.0065-0.1112) 0.0282 (0.0177-0.0386)
95% CI = 95% confidence interval
Figure 3 NDRG2 mRNA levels are down-regulated in tumor
tissue from breast cancer patients and co-vary with Myc mRNA
levels. Normalised mRNA expression of NDRG2 and Myc,
respectively, was determined in normal and affected tissue from
breast cancer patients. Lines represent mean expression.
** p < 0.005 compared to the normal group using a two-tailed
Mann-Whitney test. A weakly significant positive correlation was
found between NDRG2 and Myc mRNA levels for normal samples (p
= 0.0238) and for tumor samples (p = 0.0113), using a Spearman’s
correlation test.
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Thus, our statistical analysis was based on 3 normal and
9 tumor samples. Although we observed a significant
difference between normal and tumor tissues with
regard to NDRG2 mRNA levels, we are aware that it is
not a satisfying sample size to draw any conclusions
from, but as mentioned previously our data are consis-
tent with recent findings by others [3].
Using quantitative RT-PCR, we demonstrated that
NDRG2 mRNA levels were statistically significantly
reduced in breast cancer tissue when compared to nor-
mal tissue. Liu et al. have previously reported by semi-
quantitative PCR that there was a reduction in NDRG2
mRNA levels in 5 out of 21 breast cancer samples
tested, compared to normal tissue [16]. However, our
results are based on quantitative real-time PCR and a
slightly larger sample set (n = 35). Differences at the
mRNA level for NDRG2 are likely to be reflected at the
protein level [12] and our results are in agreement with
other studies showing that NDRG2 protein is reduced
in breast cancer [19].
Two alternative protein isoforms of NDRG2 have been
described. In the long form of NDRG2, a short stretch
of 14 amino acids is inserted N-terminal to the con-
served a/b-hydrolase fold domain, as a result of alterna-
tive splicing [11,20]. It would be interesting in future
studies to examine whether the different splice forms of
NDRG2 are under differential regulation, which could
explain the mixed expression results observed in some
cancer types and shed light on the possible function of
this protein.
In 2006 it was shown that the Myc oncoprotein could
interact with the NDRG2 promoter via Miz-1 and that
the level of Myc is inversely correlated with the level of
NDRG2 in colon cancer cell-lines undergoing differen-
tiation [12]. Since MYC is known to be either over-
expressed or amplified in many human cancers [21], it
could be responsible for the decreased levels of NDRG2
mRNA. Zhao et al. demonstrated that there is an
inverse correlation between the levels of NDRG2 and
MYC mRNA in thyroid cancer [3]. Whether this also
applies to other cancers is not known, and we therefore
quantified MYC and NDRG2 mRNA in a set of breast
cancer samples. However, we observed only a weak cor-
relation between MYC and NDRG2 mRNA expression
in normal and tumor samples from breast tissue, indi-
cating that MYC and NDRG2 are co-regulated. This
makes it unlikely that Myc acts as a repressor for
NDRG2 gene expression in breast cancer. One possibi-
lity is that Myc acts as a transcriptional activator for
NDRG2 by recruiting co-factors other than Miz-1 [22].
Alternatively, the observed correlation of MYC and
NDRG2 mRNA expression in breast tissue may result
from a shared regulatory mechanism of these genes in
the normal and tumor samples tested.
In summary, we have demonstrated that NDRG2
mRNA levels are significantly reduced in thyroid and
breast cancer, and that NDRG2 mRNA levels will be
interesting to quantify in cervix and testis cancer. Over-
expression of NDRG2 protein in cancer cell-lines results
in a marked reduction in cell proliferation, although the
precise mechanisms are unclear [5,8,23]. Since studies in
other cancer types demonstrate that high NDRG2
mRNA expression correlates with improved prognosis
[2,6,7], future studies could be aimed at developing ther-
apeutic approaches to increase NDRG2 expression in
tumor tissue.
Conclusion
In conclusion, NDRG2 mRNA levels were significantly
decreased in tumor samples from both thyroid and
breast cancer, compared to normal tissue. Our observa-
tions also indicate that cervix and testis tissues might
exhibit decreases in NDRG2 mRNA in a similar man-
ner. Finally, our results suggest that the observed reduc-
tion of NDRG2 mRNA in breast cancer correlated
weakly with MYC mRNA expression. Although expres-
sion of NDRG2 mRNA is reduced in many human
tumors, the role of NDRG2 in carcinogenesis is pre-
sently unclear.
Additional material
Additional file 1: Expression analysis of NDRG2 using a cancer
profiling array. Signal intensities from the CPA and corresponding
patient data. Data for colon cancer was published previously [1].
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